Literature DB >> 25469032

Advances in non-surgical management of primary liver cancer.

Xiao Chen1, Hai-Peng Liu1, Mei Li1, Liang Qiao1.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death worldwide. There have been great improvements in the diagnosis and treatment of HCC in recent years, but the problems, including difficult diagnosis at early stage, quick progression, and poor prognosis remain unsolved. Surgical resection is the mainstay of the treatment for HCC. However, 70%-80% of HCC patients are diagnosed at an advanced stage when most are ineligible for potentially curative therapies such as surgical resection and liver transplantation. In recent years, non-surgical management for unrespectable HCC, such as percutaneous ethanol injection, percutaneous microwave coagulation therapy, percutaneous radiofrequency ablation, transcatheter arterial chemoembolization, radiotherapy, chemotherapy, biotherapy, and hormonal therapy have been developed. These therapeutic options, either alone or in combination, have been shown to control tumor growth, prolong survival time, and improve quality of life to some extent. This review covers the current status and progress of non-surgical management for HCC.

Entities:  

Keywords:  Ablation therapy; Biotherapy; Chemotherapy; Hepatocellular carcinoma; Hormonal therapy; Percutaneous ethanol injection; Percutaneous microwave coagulation therapy; Radiofrequency ablation; Radiotherapy; Transcatheter arterial chemoembolization

Mesh:

Substances:

Year:  2014        PMID: 25469032      PMCID: PMC4248207          DOI: 10.3748/wjg.v20.i44.16630

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  67 in total

1.  Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection.

Authors:  K N Khan; H Yatsuhashi; K Yamasaki; M Yamasaki; O Inoue; M Koga; M Yano
Journal:  J Hepatol       Date:  2000-02       Impact factor: 25.083

2.  Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation.

Authors:  Soo Ryang Kim; Susumu Imoto; Taisuke Nakajima; Kenji Ando; Keiji Mita; Miyuki Taniguchi; Noriko Sasase; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi
Journal:  Hepatol Int       Date:  2009-03-21       Impact factor: 6.047

3.  Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.

Authors:  L A Dawson; C J McGinn; D Normolle; R K Ten Haken; S Walker; W Ensminger; T S Lawrence
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

4.  Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation.

Authors:  Biwei Yang; Jinghuai Zou; Jinglin Xia; Zhenggang Ren; Yuhong Gan; Yanhong Wang; Boheng Zhang; Ninglin Ge; Diane Wang; Yi Chen; Rongxin Chen; Lixin Li; Shenglong Ye; Xiangdong Wang
Journal:  Eur J Radiol       Date:  2010-03-19       Impact factor: 3.528

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 6.  The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

7.  Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors.

Authors:  Sid Kerkar; Arthur M Carlin; Richard L Sohn; Christopher Steffes; James Tyburski; Peter Littrup; Donald Weaver
Journal:  Surgery       Date:  2004-10       Impact factor: 3.982

8.  Percutaneous ethanol injection therapy in the treatment of hepatocarcinoma--results obtained from a series of 88 cases.

Authors:  Mirela Danila; Ioan Sporea; Roxana Sirli; Alina Popescu
Journal:  J Gastrointestin Liver Dis       Date:  2009-09       Impact factor: 2.008

9.  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.

Authors:  Ramesh K Ramanathan; Chandra P Belani; Deepti A Singh; Michael Tanaka; Heinz-Josef Lenz; Yun Yen; Hedy L Kindler; Syma Iqbal; Jeff Longmate; Philip C Mack; Georg Lurje; Regina Gandour-Edwards; Janet Dancey; David R Gandara
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-24       Impact factor: 3.333

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  21 in total

1.  "Homomorphic" Tumor Metastases as an Endodiagnostic Clue: A Case Series of Renal-Cell Carcinoma Metastatic to the Stomach.

Authors:  Simcha Weissman; Tej I Mehta; Alex Zhornitskiy; Rashmi Tondon; James H Tabibian
Journal:  Gastrointest Tumors       Date:  2019-09-12

2.  Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.

Authors:  Jun Qian; Elsie Oppermann; Andreas Tran; Ulli Imlau; Kun Qian; Thomas Josef Vogl
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

3.  The clinicopathological significance of miR-149 and PARP-2 in hepatocellular carcinoma and their roles in chemo/radiotherapy.

Authors:  Ling Lin; Yang-de Zhang; Zi-Yu Chen; Yuxiang Chen; Cai-Ping Ren
Journal:  Tumour Biol       Date:  2016-06-14

4.  Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors.

Authors:  Yoshikuni Inokawa; Kenichi Inaoka; Fuminori Sonohara; Masamichi Hayashi; Mitsuro Kanda; Shuji Nomoto
Journal:  Oncol Lett       Date:  2016-09-15       Impact factor: 2.967

5.  The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.

Authors:  Xiaorong Jiang; Jingxia Wang; Kaili Zhang; Siyuan Tang; Caiping Ren; Yuxiang Chen
Journal:  Med Oncol       Date:  2015-03-25       Impact factor: 3.064

6.  A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma.

Authors:  Wenmin Hu; Yongmei Shi; Tongqin Han; Caiyun Liu; Xipeng Cao; Guangjun Shi; Wenjing Zhu
Journal:  Front Genet       Date:  2022-05-03       Impact factor: 4.772

7.  High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma.

Authors:  Jian-Dong Shen; Shou-Zhong Fu; Lin-Ling Ju; Yi-Fang Wang; Feng Dai; Zhao-Xiu Liu; Han-Zheng Ji; Jian-Guo Shao; Zhao-Lian Bian
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

Review 8.  Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.

Authors:  Jian-Jun Gao; Zhen-Yan Shi; Ju-Feng Xia; Yoshinori Inagaki; Wei Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation.

Authors:  Tao Jiang; Xianjie Zhang; Jing Ding; Bingwei Duan; Shichun Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

10.  Transarterial oily chemoembolization with lidamycin shows potent therapeutic efficacy in VX2 rabbit liver tumor.

Authors:  Genshen Zhong; Jinsong Qi; Shuhua Huo; Huichao Xue; Zhishan Xu; Jinsong Li; Yanjun Zhou; Minna Wu; Liang Li
Journal:  Onco Targets Ther       Date:  2015-10-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.